Compare Best Buy Co Inc (BBY) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs GSK plc — how do they compare? Best Buy Co Inc trades at $85.19 (market cap $17.70B), while GSK plc trades at $51.46 (market cap $101.55B). The key difference: GSK plc is far larger — about 5.7× Best Buy Co Inc's market cap, and Best Buy Co Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| BBY | GSK | |
|---|---|---|
Market Cap | $17.70B | $101.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $84.00 | $61.18 |
52-Week Low | $55.52 | $36.20 |
Enterprise Value | $20.08B | $122.16B |
Dividend Yield | 4.57% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $81.65, down 1.39% on the day, with a bullish technical outlook and strong recent earnings beats. The stock shows robust profitability with a 39.1% ROE and trades at attractive valuations (P/E 15.12, P/S 0.41). Recent news highlights leadership changes and strategic shifts toward higher-margin businesses like marketplace and retail media, supported by new product launches such as RGB LED TVs and Meta VR partnerships.
The outlook is cautiously optimistic with a consensus price target of $82.17 offering modest upside. Key opportunities include dividend yield near 5% and earnings momentum, while risks involve revenue declines, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is mixed with 34% buy ratings, reflecting balanced views on growth potential versus execution challenges.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
